C&EN logo The Newsmagazine of the Chemical World
Home Current Issue ChemJobs Join ACS
Support
Latest News
Business
Government & Policy
Science/Technology
Careers and Employment
ACS News
topics
   
Support
 
Support
How to log in
Contact Us
Site Map
   
About C&EN
About the Magazine
How to Subscribe
How to Advertise
Chemcyclopedia

Latest News RSS Feed

latest news RSS feedWhat is this?

   
Join ACS
Join ACS
  Latest News  
  January 3, 2005
Volume 83, Number 01
p. 7
 

STRATEGY

  AstraZeneca To Overhaul Clinical Processes
 
  RICK MULLIN  
     
 

AstraZeneca CEO Sir Tom McKillop has launched an overhaul of his company's clinical and regulatory drug development regime. The move follows news that FDA may remove AstraZeneca's cancer drug Iressa (gefitinib) from the market in light of clinical test results that show it failed to prolong the lives of patients with advanced lung cancer.

NOTW_McKillop.tifcxd
McKillop
ASTRAZENECA PHOTO
The move also follows FDA's rejection of the company's blood-thinning drug Exanta (ximelagatran) in October and questions regarding the safety of Crestor (rosuvastatin), the company's cholesterol-lowering drug, aired during congressional hearings last month.

McKillop has appointed Executive Vice President John Patterson to the newly created board position of executive director responsible for development. Patterson, he says, is charged with implementing substantial changes in clinical organization and processes and with improving regulatory capabilities and interactions with regulatory authorities.

"These recent disappointments, set in a more hostile environment toward pharmaceutical stocks, have resulted in a substantial loss of value," McKillop says. "I am determined to improve our development and regulatory performance and restore confidence in the company and value to shareholders."

Iressa received expedited FDA approval in May, pending results of clinical trials. FDA is facing increased criticism of its assessment of safety risks during the drug approval process and of its safety monitoring of drugs on the market.

 
     
  Chemical & Engineering News
ISSN 0009-2347
Copyright © 2005
 


Related Story
Tailored Cancer Therapy
[C&EN, May 4, 2004]  


 
E-mail this article
to a friend
Print this article
  E-mail the editor